Molnar-Stanciu D, Guimas V, Bensalem A, Thiery-Vuillemin A
Service d'oncologie médicale, CHU Jean-Minjoz, boulevard Flemming, 25000 Besançon, France.
Pathol Biol (Paris). 2012 Aug;60(4):254-63. doi: 10.1016/j.patbio.2012.05.012. Epub 2012 Jun 22.
Scientific advances in molecular biology and understanding of oncogenesis have lead to anticancer molecular targeted therapies. They encompass monoclonal antibodies binding to active membrane epitopes and small molecules interfering with enzymatic reactions essential to cancer cell survival (oncogene addiction). These pathways may be optimal targets. Clinical benefits achieved using these targeted agents have been outstanding both in localized and metastatic disease.
We conducted a survey of literature analyzing activity and safety of targeted agents approved by FDA and/or FDA for the treatment of patients with breast cancer: anti-HER2 and antiangiogenic agents.
Activity and main toxicities of these targeted agents are described according to signaling pathway targeted as well as stage of breast cancer.
Availability of these targeted therapies has indeed transformed the outcome of subgroups of breast cancer to the expense of acceptable and manageable side effects, as compared to classical cytotoxics to which they are nevertheless combined.
分子生物学的科学进展以及对肿瘤发生的理解催生了抗癌分子靶向疗法。它们包括与活性膜表位结合的单克隆抗体以及干扰癌细胞存活所必需的酶促反应（癌基因成瘾）的小分子。这些途径可能是最佳靶点。使用这些靶向药物在局部和转移性疾病中取得的临床益处都非常显著。
我们对文献进行了一项调查，分析了美国食品药品监督管理局（FDA）和/或欧洲药品管理局（EMA）批准的用于治疗乳腺癌患者的靶向药物的活性和安全性：抗HER2药物和抗血管生成药物。
根据所靶向的信号通路以及乳腺癌的阶段，描述了这些靶向药物的活性和主要毒性。
与传统细胞毒性药物联合使用时，这些靶向疗法的可用性确实改变了乳腺癌亚组的治疗结果，但代价是出现了可接受和可管理的副作用。
